Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
This study is currently recruiting participants.
The purpose of this study is to test the safety of a study drug called duvelisib.
Study Type: Interventional
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
Relapsed/Refractory T-cell Lymphomas
Phase: Phase 1
External Link: https://clinicaltrials.gov/ct2/show/NCT02783625